Risk-Stratified Axillary Surgery Shifts Survival in Older Breast Cancer Patients
Older women with early-stage breast cancer and 1–2 positive lymph nodes did not behave as a uniform group. In a large retrospective analysis, the survival signal depended on biologic and clinicopathologic risk, and the best axillary strategy changed with it. Across the overall cohort, sentinel lymph node biopsy plus radiotherapy produced better overall survival and breast cancer-specific survival than the other axillary approaches after propensity score matching. For patients with more favorable disease, however, escalating local treatment offered little measurable gain over less aggressive surgery.
The clinical question is familiar to breast surgeons and radiation oncologists: when is it safe to stop after sentinel staging, and when does the axilla still need treatment beyond biopsy? In older patients, the tradeoff is sharper because postoperative morbidity from axillary lymph node dissection can be substantial, while competing medical risks may limit the value of maximal surgical clearance. This analysis argues that age alone should not drive de-escalation. Tumor biology and nodal burden still matter.
What the Cohort Showed Across 8,977 SEER Patients
Investigators reviewed two cohorts: 8,977 patients diagnosed between 2010 and 2019 in the SEER database and 106 patients treated at a single Chinese center between 2018 and 2021. The SEER cohort underwent propensity score matching, leaving 5,858 matched patients split evenly between sentinel lymph node biopsy and axillary lymph node dissection groups, 2,929 in each arm. Median follow-up was 45 months. Survival analyses used multivariate Cox regression, and locoregional recurrence was examined with logistic regression.
In the matched SEER cohort, SLNB plus radiotherapy was associated with superior overall survival and breast cancer-specific survival compared with other axillary strategies. The paper also identified a set of independent predictors of worse breast cancer-specific survival: age older than 76 years, grade II–III disease, two positive axillary nodes, tumor size from 1.4 to 5 cm, triple-negative subtype, SLNB without radiotherapy, and ALND without radiotherapy. Each of those variables points toward a higher residual burden of microscopic disease or a more aggressive tumor phenotype, both of which increase the chance that local control will matter.
The hazard ratios sharpen the picture. Age older than 76 years carried an HR of 2.047 for breast cancer-specific survival, grade II–III disease an HR of 2.060, and triple-negative subtype an HR of 2.289. The omission of radiotherapy after either SLNB or ALND also tracked with worse outcomes, with HRs of 1.873 and 1.771, respectively. Those estimates do not prove causation, but they are consistent with a biologic model in which microscopic residual disease in the breast and regional nodes continues to seed recurrence when local therapy is pared back too far.
One result stands out immediately.
In patients who still carried higher-risk features, removing the axilla from treatment did not remove the hazard.
High-Risk Patients Derived the Clearest Benefit From SLNB Plus RT
The subgroup data separated the cohort into high-, intermediate-, and low-risk strata. In the high-risk group, 5-year breast cancer-specific survival reached 91.3% with SLNB plus radiotherapy, compared with 76.6% with SLNB without radiotherapy, 91.5% with ALND plus radiotherapy, and 84.5% with ALND without radiotherapy. In the intermediate-risk group, the corresponding 5-year rates were 96.9%, 92.3%, 94.9%, and 92.7%. Kaplan-Meier analysis confirmed significant survival benefit for SLNB plus radiotherapy in both high- and intermediate-risk patients.
The recurrence pattern mirrors those survival curves. For locoregional recurrence, the low-risk group had no events across all four treatment arms over 5 years. In the intermediate-risk group, 5-year locoregional recurrence was 6.67% with SLNB plus radiotherapy, 33.33% with SLNB without radiotherapy, 7.69% with ALND plus radiotherapy, and 20.00% with ALND without radiotherapy. In the high-risk group, the corresponding rates were 7.69%, 50.00%, 7.70%, and 42.86%. Those differences are not subtle. They suggest that radiotherapy compensated for a degree of surgical de-escalation, while surgery alone was less protective in patients whose disease biology already signaled higher risk.
The structure of the data also helps explain why a one-size-fits-all axillary policy fails in older adults. SLNB samples the basin rather than clearing it; when the residual risk is low, that may be enough. When the tumor is larger, higher grade, triple-negative, or associated with two positive nodes, microscopic disease likely remains beyond the sentinel basin, and regional irradiation becomes a biologically plausible way to sterilize disease left behind after limited surgery.
Why Low-Risk Patients May Not Need More Surgery
The low-risk cohort behaved differently. Five-year breast cancer-specific survival was 96.3% with SLNB plus radiotherapy, 95.2% with SLNB without radiotherapy, 96.5% with ALND plus radiotherapy, and 94.3% with ALND without radiotherapy. No statistically significant differences emerged among the four strategies, and there were no locoregional recurrences within 5 years in any arm.
For clinicians, this is the subgroup that most clearly supports restraint. If recurrence risk is already minimal, the incremental value of ALND or routine radiotherapy may be too small to justify the morbidity burden, particularly in a patient population already facing age-related frailty and comorbid illness. The study does not provide a permission slip to omit treatment broadly; it shows that omission may be reasonable when clinicopathologic risk is low and the axillary burden is limited to 1–2 positive nodes.
Practical Meaning for Surgeons and Radiation Oncologists
The study’s main message is not that every older patient should receive radiotherapy after sentinel node biopsy. It is narrower. In elderly patients with early-stage disease and 1–2 positive nodes, axillary management should be guided by risk factors rather than age alone. SLNB plus radiotherapy appears to be the safer compromise for intermediate- and high-risk patients, preserving disease control while avoiding the added morbidity of full dissection. For low-risk patients, SLNB alone may be sufficient.
This has direct bedside implications. A patient older than 76 years with grade II–III disease, a 1.4 to 5 cm tumor, triple-negative biology, or two positive nodes belongs in a different conversation from a patient with a small, favorable tumor and minimal nodal involvement. The first patient may need regional treatment to suppress recurrence risk; the second may be harmed more by overtreatment than by omission. The data support that split.
The study remains retrospective, and the two cohorts differed in design and size, with the SEER cohort far larger than the single-center Chinese group. Follow-up was a median of 45 months, which is useful but still not long enough to settle every question about late recurrence in hormone receptor-positive disease. Even so, the direction of effect was consistent: radiotherapy mattered most when the disease burden was higher, and omission of both ALND and radiotherapy was least defensible in the highest-risk patients. The remaining uncertainty is not whether risk stratification is useful, but how precisely individual patients should be assigned to de-escalated versus combined local therapy in day-to-day practice.